Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 129.73B P/E 18.00 EPS this Y -90.70% Ern Qtrly Grth -12.90%
Income 8.02B Forward P/E 8.64 EPS next Y 911.40% 50D Avg Chg -4.00%
Sales 45.01B PEG -16.53 EPS past 5Y 13.30% 200D Avg Chg -12.00%
Dividend 4.00% Price/Book 4.03 EPS next 5Y -4.17% 52W High Chg -24.00%
Recommedations 2.70 Quick Ratio 1.24 Shares Outstanding 2.03B 52W Low Chg 3.00%
Insider Own 0.10% ROA 5.63% Shares Float 2.02B Beta 0.39
Inst Own 78.93% ROE 26.53% Shares Shorted/Prior 35.12M/32.65M Price 61.75
Gross Margin 76.63% Profit Margin 17.83% Avg. Volume 8,754,443 Target Price 55.95
Oper. Margin 17.01% Earnings Date Apr 25 Volume 9,548,659 Change 0.36%
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company News
08:30 AM 2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
04/15/24 Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
04/15/24 In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions
04/15/24 Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
04/12/24 The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
04/11/24 If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
04/11/24 ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
04/11/24 Building a Better Future: Bristol Myers Squibb 2023 ESG Report
04/11/24 A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE
04/10/24 Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
04/10/24 The Pharmaceutical Industry Finds Itself At A Historical Crossroads
04/10/24 2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
04/09/24 Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
04/09/24 Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
04/09/24 3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
04/08/24 Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
04/08/24 Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
04/08/24 KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
04/08/24 FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
04/08/24 Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
BMY Chatroom

User Image MrPHD_Certifed Posted - 1 hour ago

$SLS $MRK $BMY $ABBV Who is going to buy us out?

User Image Shanghi18 Posted - 2 hours ago

$BMY finally got filled AH for a nice chunk at 47.85 for a swing. I say it bops back over 48 2maro or I'll just hang out with a bunch at 50.30. whatev

User Image FridayGuy Posted - 2 hours ago

$BMY What the fooook?

User Image maker11 Posted - 2 hours ago

@MrPHD_Certifed @GPS_OS_21_vs_SOC_5 @AndersKingern_ $BMY has 18,934 “watchers”… and on and on…

User Image Shanghi18 Posted - 4 hours ago

$BMY well, the $48 dam has been breached. But no worries. Cuz the ST sentiment chart says it's Extremely bullish. TG

User Image InvestorPlace Posted - 6 hours ago

3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500 $SON $OZK $BMY https://investorplace.com/2024/04/3-undervalued-dividend-stocks-to-buy-now-to-beat-the-sp-500/

User Image SPG565 Posted - 7 hours ago

$BMY Go Green, dummy!

User Image TheSkipper Posted - 8 hours ago

$BMY Can it hold at the triple bottom support. If not, its going lower.

User Image Capitulation_0 Posted - 8 hours ago

$BMY think they can do 4B+ by the way.

User Image Capitulation_0 Posted - 8 hours ago

$CYTK When $MYOK was bought, this was the sentiment: “I think it is a typical acquisition premium for our sales expectations for mavacamten as we had estimates in the initial (and lowest risk) indication of obstructive hypertrophic cardiomyopathy of about $2.5 billion by 2026,” Wedbush analyst David Nierengarten said. $CYTK at 13B isn't expensive, in fact, it's cheaper than $MYOK when it got sold for 13.1B. One other reason why $BMY bought $MYOK was that they wanted to decrease dependency on cancer drug portfolio. Same applies to other BP's.

User Image JerryMalone32 Posted - 9 hours ago

@Fatpocketz @spderman I'm right there with fatpockets. Down over a million with $blue and over a million also with $tsvt ... Still holding because I believe $blue will do well with SCD, and because I believe $tsvt could get bought out by $bmy .... But nothing Obenshain & Co. do shocks me anymore. Not since that PRV fuck-up. They're the absolute worst. They make Leschly look competent.

User Image Jack90 Posted - 9 hours ago

Hiding here $LLY $PFE $BMY $JNJ Stable and safety probably better here to hide at correction and get dividends

User Image Jack90 Posted - 10 hours ago

$LLY $PFE $BMY $JNJ Stable and safety probably better here to hide at correction

User Image StockednLoaded Posted - 10 hours ago

$IOVA $BMY Get it done Bristol Meyers! Stock been dead for a decade and they've got the cash, own Ipi/Nivo and have an investment in Obsidian for IL-15. Profits will boom after Trump cuts corporate taxes. Time to pioneer the here and now game-changing advancement in the fight against the Big C. Allez! Dale! Lezzzgooo!

User Image JoeSpringer Posted - 11 hours ago

$SAVA Takeout Value Comparison 10:30 ET Stream Action: https://youtube.com/live/4PejJdE9sp4 $BMY $IBB $LABU $XBI

User Image sm1111 Posted - 11 hours ago

$BMY What is wrong here ?

User Image BillyBobsax Posted - 12 hours ago

$BMY $BMY Q1 2024 Estimate Trends Current: $-4.43 1 month ago: $1.62 3 months ago: $1.89

User Image BillyBobsax Posted - 13 hours ago

$BMY Why did Wall Street Q1 per share revenue drop into negative numbers?

User Image Game_Day Posted - 1 day ago

Latest alerts 🔔 Optoons $JNJ ⭐️ 8% $BMY ⭐️ 7% Stocks $DYNT ⭐️ 40% $DRMA ⭐️ 20% Free alert $MPW ⭐️ 3%

User Image headsortails2066 Posted - 1 day ago

$BMY is it just me or does BMY keep dumping ten minutes before the bell every day for a couple weeks now?

User Image FridayGuy Posted - 1 day ago

$BMY If you even push out the Daily chart to 5 years you can see the $48.25 level support line is so strong here I don't think it will breakdown below that, especially as the presidential elections are about to begin and lobbyists getting involved in selling more healthcare; We just have to have good earnings on 4/25/24 to really bounce up hard to the upside

User Image UltimateTrader_22 Posted - 2 days ago

$NRXP @NRxPharma NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy https://www.zacks.com/stock/news/2250692/nrx-pharmaceuticals-nrxp-upgraded-to-strong-buy-heres-what-you-should-know?art_rec=quote-stock_overview-zacks_news-ID01-txt-2250692 $BMY $PFE $JNJ

User Image UT_RPh Posted - 2 days ago

$AUPH $BMY down 28% in a year.. need to buy $AUPH for $15-$18

User Image basedpicks Posted - 2 days ago


User Image JDR1983 Posted - 2 days ago

Buying more $BMY!!!

User Image FridayGuy Posted - 2 days ago

$BMY Looking like the major bounce off of $48.23 we needed; Healthcare stock sector are due for a big move up

User Image Thesis_Alexander Posted - 2 days ago

$BMY "KRAZATI WITH CETUXIMAB SHOWS CLINICALLY MEANINGFUL ACTIVITY AS A TARGETED TREATMENT OPTION FOR PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER" https://biopharma-asia.com/sections/krazati-with-cetuximab-shows-clinically-meaningful-activity-as-a-targeted-treatment-option-for-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer/

User Image Thesis_Alexander Posted - 2 days ago

$BMY " "BMS’ oral plaque psoriasis drug Sotyktu gets reimbursement starting April" The approval for reimbursement is in Korea. https://www.koreabiomed.com/news/articleView.html?idxno=23717

User Image GPS_OS_21_vs_SOC_5 Posted - 2 days ago

$SLS @Wut_About_Bob as a matter of fact in the Ph2 Gps Keytruda $MRK published abstract trial for advanced, platinum resistant/refractroy ovarain cancer patients, the Memorial Sloan Kettering and Merck Doctors said Gps immunotherapy was directly correlated to increased survival, (13 months w Key alone vs 18.4 w Gps - obviously they see Gps working) and Gps would work even better in a Remission maintenance setting - like the current P3, imminently due P3. note: elahere was approved in this same setting proc w 16.4 months of os, $IMGN and got bought for 10.1b. $MRK / $BMY will be paying a premium for a deRisked Gps once the P3 is In, any day now.

User Image MrPHD_Certifed Posted - 2 days ago

$SLS $MRK $BMY Phase 3 Interim worth hundreds of millions We are partnered with two big pharma companies

Analyst Ratings
Wells Fargo Equal-Weight Feb 6, 24
Redburn Atlantic Neutral Feb 6, 24
B of A Securities Neutral Jan 3, 24
B of A Securities Buy Dec 27, 23
Cantor Fitzgerald Neutral Nov 15, 23
Deutsche Bank Hold Nov 9, 23
Daiwa Capital Neutral Nov 2, 23
Goldman Sachs Buy Oct 30, 23
Morgan Stanley Underweight Oct 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Dec 05 Buy 49.78 2,000 99,560 82,672 12/07/23
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Nov 28 Buy 48.86 3,071 150,049 79,384 11/30/23
Samuels Theodore R. II Director Director Nov 20 Buy 49.81 8,500 423,385 35,500 11/21/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Aug 24 Sell 61.25 17,986 1,101,642 27,868 08/28/23
Plenge Robert M EVP, Chief Research.. EVP, Chief Research Officer Aug 03 Sell 61.14 732 44,754 6,584 08/07/23
VESSEY RUPERT EVP & President, Res.. EVP & President, Research May 03 Sell 67.06 50,385 3,378,818 47,751 05/04/23
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 06 Sell 74.65 240,000 17,916,000 236,104 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Feb 06 Sell 74.69 11,183 835,258 23,043 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Nov 09 Sell 80.45 16,250 1,307,312 34,226 11/14/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Option 54.85 52,604 2,885,329 102,989 11/09/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Sell 78.88 45,910 3,621,381 57,079 11/09/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Sell 71.32 133,951 9,553,385 119,786 09/15/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Option 48.49 123,277 5,977,702 223,737 09/15/22
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Sep 14 Sell 70.75 25,000 1,768,750 50,476 09/15/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Jun 13 Sell 74.04 30,000 2,221,200 551,104 06/14/22
LEUNG SANDRA EVP, General Counsel EVP, General Counsel Jun 06 Sell 74.89 65,000 4,867,850 308,627 06/07/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Mar 21 Sell 71.52 25,000 1,788,000 581,524 03/23/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Option 53.64 47,305 2,537,440 93,613 03/18/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Sell 69.25 74,559 5,163,211 50,385 03/18/22
Santiago Karen Murphy SVP & Controller SVP & Controller Mar 14 Sell 69.195 6,577 455,096 16,704 03/16/22
BOERNER CHRISTOPHER S. EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 14 Sell 69.197 29,532 2,043,526 41,966 03/16/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 24 Sell 67 30,000 2,010,000 453,455 02/28/22
von Autenried Paul EVP, Chief Informati.. EVP, Chief Information Officer Nov 22 Sell 57.19 51,134 2,924,353 63,536 11/24/21
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Option 48.03 52,213 2,507,790 98,355 11/23/20
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Sell 61.28 57,591 3,529,176 51,343 11/23/20